Modulation of Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes of Patients With Parkinson's Disease or Amyotrophic Lateral Sclerosis

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Deferiprone (Primary)
Indications Amyotrophic lateral sclerosis; Iron overload; Parkinson's disease
Focus Pharmacodynamics
Acronyms LymphoEnergy

30 Mar 2020 Status changed from active, no longer recruiting to completed.
25 Apr 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
25 Apr 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2019.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com